Envision a world
where no patient
is left behind
Despite decades of innovation in antibody-based therapeutics, many diseases lack efficacious treatment options.
Attovia aims to change this.
By utilizing our ATTOBODY technology, we are developing medicines that offer first-in-class mechanisms of action and that can deliver breakthrough efficacy where existing treatments fall short.
Envision
a world
where no
patient
is left behind
Despite decades of innovation in antibody-based therapeutics, many diseases lack efficacious treatment options.
Attovia aims to change this.
By utilizing our ATTOBODY technology, we are developing medicines that offer first-in-class mechanisms of action and that can deliver breakthrough efficacy where existing treatments fall short.
ATTOBODY®
Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY, our proprietary biologics platform, to generate first-in-class and best-in-class bispecifics and multispecifics.
ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which offer best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of bispecifics and multispecifics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development.
Interested in learning more or discussing partnering opportunities?
Leading the way to first-in-class therapeutics
We are a seasoned team of drug development leaders passionate about bringing new and improved medicines to patients.
Tao Fu, MBA, M.S.
Chief Executive Officer
Tao Fu is the Founder and Chief Executive Officer at Attovia, where he brings over 25 years of Business Development, General Management, Operations, Strategy, and Commercial leadership experience in the pharmaceutical industry. He also holds a Venture Partner position with Frazier Life Sciences.
Prior to founding Attovia, Mr. Fu served as President & Chief Operating Officer and then Chief Strategy Officer for Zai Lab, where he held a broad set of responsibilities including Strategy, Operations, Business Development, CMC, Quality, and other corporate functions. Prior to Zai Lab, he was EVP, Chief Commercial and Business Officer of Portola Pharmaceuticals, where he led Commercial Operations, Sales, and Business Development. Prior to his role at Portola, Mr. Fu held a number of leadership positions in Business and Corporate Development, including leading the Business Development and M&A functions at Bristol Myers-Squibb and Johnson & Johnson. Earlier in his career, he was a consultant at McKinsey & Company.
Tao received an M.S. in Biology from the University of Rochester, and an MBA in Finance and Marketing from Vanderbilt University. He completed his undergraduate studies in Biology at Tsinghua University and is a Chartered Financial Analyst (CFA).
Chief Business Officer
Dr. Zaneta Odrowaz is the Chief Business Officer and Co-Founder at Attovia, leading Business Development and Operations for the company. She also holds a seat on the Frazier Life Sciences team as a Vice President of Company Creation.
Prior to Attovia, Zaneta served full time at Frazier, focusing on company creation activities and advising on private and public investment opportunities. Before joining Frazier, Zaneta served on the Corporate Development team at Amunix Pharmaceuticals, where she played a key role in the $1Bn+ acquisition of the company by Sanofi and helped raise over $100M in capital. Prior to her role at Amunix, Dr. Odrowaz was the Chief of Staff to the General Manager at Philips Neuro, where she also led the Business Development and Strategy functions. Earlier in her career, she served biopharma and PE clients as a management consultant at McKinsey.
Dr. Odrowaz earned a Ph.D. in Gene Expression from the University of Manchester, UK, where she held a Wellcome Trust Fellowship. She also received a Master’s degree in Biotechnology from the Jagiellonian University in Poland, and has completed a postdoctoral fellowship in Neuroepigenomics as a Walter V. and Idun Berry fellow at Stanford University.
Chief Scientific Officer
Dr. Petter Veiby is the Chief Scientific Officer and Co-Founder at Attovia, responsible for the company’s R&D strategy. He has >25 years industry experience primarily in drug discovery and early development, and BD search and evaluation.
Prior to joining Attovia, Petter was the Head of Alliances and BD Search and Evaluation at Zai Lab and built a team to manage 15 alliances and collaborations across discovery through commercialization. Before Zai Lab, he spent over 20 years in various leadership roles in the Oncology Drug Discovery Unit at Millennium/Takeda. Petter has always had a passion for biotherapeutics. In his role as Global Head of Biotherapeutics at Takeda, he led the biotherapeutics strategy growing Takeda’s capabilities and pipeline of biologics through internal infrastructure build and numerous strategic partnerships leading to a deep pipeline of ADCs, bispecific immune cell engagers, and cell therapies. While at Millennium, he led the biological validation of novel targets, and oversaw numerous projects delivering IND-ready development candidates resulting in drugs like Ninlaro and Pevonedistat, with his efforts contributing to the acquisition of Millenium by Takeda.
Dr. Veiby did his Ph.D. and postdoc studies in hematopoietic stem cell biology at University of Oslo in Norway and at Hipple Cancer Research Center/OSU. He has authored/co-authored >50 papers in peer reviewed journals.
Chief Medical Officer
Dr. Hubert Chen is Chief Medical Officer at Attovia. He is an accomplished physician-scientist with 25 years of clinical and industry experience spanning all phases of drug development from first-in-human to launch.
Prior to joining Attovia, Hubert served as Senior Vice President of Clinical Development at Krystal Biotech, where he played an instrumental role in the FDA approval of the first topical gene therapy, beremagene geperpavec, for the treatment of dystrophic epidermolysis bullosa, while also expanding the pipeline beyond dermatology by initiating first-in-human studies in multiple new therapeutic areas. Before Krystal, Hubert was Principal Medical Director at Genentech, where he served for over a decade. During his tenure there, he led the FDA approval for omalizumab in chronic spontaneous urticaria and was responsible for the advancement of numerous early-stage programs in the respiratory and immunology portfolio, including novel bispecific antibodies, small molecules, and drug-device combination products.
Dr. Chen began his career as an Assistant Professor in the pulmonary division at UCSF and has published over 50 peer-reviewed scientific articles in the fields of allergy/immunology, respiratory medicine, and dermatology. He is board-certified in Pulmonary Medicine, Critical Care Medicine, and Internal Medicine. He received his MD from Stanford, where he also completed his internship and residency. He received his MPH from Harvard and completed his pulmonary fellowship at UCSF.
Chief Technology Officer
Dr. Hangjun Zhan is the Chief Technology Officer and Co-Founder at Attovia, where he brings nearly 30 years of drug discovery experience in the biotech industry. He is a highly regarded protein biochemist/ biophysicist/inventor and holds over 75 published patents.
Prior to Attovia, Dr. Zhan was the Chief Scientific Officer at Alamar Biosciences, where he initiated therapeutics effort using Attobody as discovery platform. Before Alamar, Hangjun was the CSO at KindredBio/Elanco. In this role, he built the R&D function and produced a top tier biotherapeutic pipeline, contributing to the acquisition by Elanco in 2021. Prior to his role at KindredBio, he served as an Executive Member at Aragen and established and headed the Protein Biochemistry team at Exelixis. In the latter role, he contributed to the discovery of four drugs that later obtained market approvals and more than 20 oncology drug candidates. Earlier in his career, Hangjun led the Protein Chemistry group at Celera.
Dr. Zhan earned his Ph.D. from the University of Washington and completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School.
Vice President of Discovery and Translational Biology
Dr. David Bellovin is Vice President and Co-Founder of Attovia, serving as the Head of Discovery and Translational Biology.
Prior to Attovia, Dr. Bellovin served as Senior Director at Zai Lab US, overseeing Discovery Biology and In Vivo Pharmacology. He directed various functions involved in target discovery and validation, as well as preclinical development for oncology and inflammatory disease, including leading a program in immuno-oncology. Before joining Zai Lab, David was a Director of Pharmacology at Five Prime Therapeutics, managing the in vivo efforts in oncology and immuno-oncology and leading multiple clinical- and non-clinical-stage programs.
Dr. Bellovin earned his Ph.D. in Experimental Pathology from Harvard Medical School and completed his postdoctoral work at Stanford University. He received undergraduate degrees in Biochemistry and Molecular and Cellular Biology from the University of Arizona.
Vice President of Project Management and Portfolio Strategy
Dr. Veit Schmelmer is Vice President of Attovia, leading Project Management and Portfolio Strategy for the company. Veit has over 25 years of experience directing the development of novel therapies for cancer, autoimmune disorders, and infectious diseases at leading biopharmaceutical companies. Before joining Attovia, he was a Senior Vice President of Project and Alliance Management at Vor Bio where he oversaw the management of clinical research programs to advance the company’s engineered hematopoietic stem cell platform. Previously, he was a Vice President at Magenta Therapeutics where he directed the development of a novel biologic designed to mobilize stem cells. Prior, Veit held the position of Vice President of Portfolio Strategy at Mersana Therapeutics with responsibility for project leadership, alliance management, and portfolio strategy. Veit also served as Global Project Leader for Takeda with responsibility for global asset strategies for new pipeline projects, overseeing programs in oncology and immunology from late-stage discovery through approval. Notably, Veit directed the global development of Entyvio® through clinical development, MAA/BLA review, global approvals, and launch. Veit began his career at Boehringer Ingelheim where he held positions of increasing seniority in Germany, the U.S., and Japan.
Veit earned his Ph.D. in Pharmaceutical Technology and Biopharmaceutics from Heidelberg University. He is a board-certified pharmacist in Germany with a specialist degree in Pharmaceutical Technology.
Start making a difference!
At Attovia, we value integrity, learning, performance, innovation, and collaboration. We work together, celebrate our successes together, and strive to make Attovia a place where everyone can grow.
Want to join the Attovia team? Let’s talk.
Start making a difference!
At Attovia, we value integrity, learning, performance, innovation, and collaboration. We work together, celebrate our successes together, and strive to make Attovia a place where everyone can grow.
Want to join the Attovia team? Let’s talk.